Publications

　　 2012　 2011　 2010　 2009 　 2008

2009

 

Das D, Koh Y, Tojo Y, Ghosh AK, and Mitsuya H. Prediction of Potency of Protease Inhibitors Using Free Energy Simulations with Polarizable Quantum Mechanics-Based Ligand Charges and a Hybrid Water Model. J Chem Inf Model. 49(12):2851-2862, 2009.

  Michailidis E, Marchand B, Kodama EN, Singh K, Matsuoka M, Kirby KA, Ryan EM, Sawani AM, Nagy E, Ashida N, Mitsuya H, Parniak MA, and Sarafianos SG. Mechanism of inhibition of HIV-1 reverse transcriptase by 4’-Ethynyl-2-fluoro-2’-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J Biol Chem. 284(51):35681-35691, 2009.
 

Roshorm Y, Hong JP, Kobayashi N, McMichael AJ, Volsky DJ, Potash MJ, Takiguchi M, and Hanke T. Novel HIV-1 clade B candidate vaccines designed for HLA-B*5101+ patients protected mice against chimaeric ecotropic HIV-1 challenge. Eur J Immunol. 39(7):1831-1840, 2009.
Watanabe T, Yasuoka A, Tanuma J, Yazaki H, Honda H, Tsukada K, Honda M, Gatanaga H, Teruya K, Kikuchi Y, and Oka S. Serum (1-->3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis. 49(7):1128-1131, 2009.
  Davaalkham J, Hayashida T, Tsuchiya K, Gatanaga H, Nyamkhuu D, and Oka S. Allele and Genotype Frequencies of Cytochrome P450 2B6 Gene in a Mongolian Population. Drug Metab Dispos. 37(10):1991-1993, 2009.
Sakaguchi N, Toda T, Nakaya T, Kitabatake M, Maeda K, and Kuwahara K. Generation of High Affinity Monoclonal Antibodies for the Prevention of HIV Infection. Recent Pat DNA Gene Seq. 3(2):88-95, 2009. (Review)
  Ghosh AK, Kulkarni S, Anderson DD, Hong L, Baldridge A, Wang YF, Chumanevich AA, Kovalevsky AY, Tojo Y, Amano M, Koh Y, Tang J, Weber IT, Mitsuya H. Design, Synthesis, Protein-Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug Resistance. J Med Chem. 52(23):7689-7705, 2009.
  Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, Tanoue N, Hamada A, and Saito H. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull. 32(9):1588-1593, 2009.

Hattori S, Ide K, Nakata H, Harada H, Suzu S, Ashida N, Kohgo S, Hayakawa H, Mitsuya H, and Okada S. Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice. Antimicrob Agents Chemother.  53(9):3887-3893, 2009.

Ghosh AK, Leshchenko-Yashchuk S, Anderson DD, Baldridge A, Noetzel M, Miller HB, Tie Y, Wang YF, Koh Y, Weber IT, and Mitsuya H. Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies. J Med Chem. 52(13):3902-3914, 2009.
Watanabe K, Honda M, Watanabe T, Tsukada K, Teruya K, Kikuchi Y, Oka S, and Gatanaga H. Emergence of raltegravir-resistant HIV-1 in the central nerve system. Int J STD AIDS. (case report) in press

Zheng N, Fujiwara M, Ueno T, Oka S, and Takiguchi M. Strong ability of Nef-specific CD4+ cytotoxic T cells to suppress human immunodeficiency virus type 1 (HIV-1) replication in HIV-1-infected CD4+ T cells and macrophages. J Virol. 83(15):7668-7677, 2009.
Kamimura M, Watanabe K, Kobayakawa M, Mihara F, Edamoto Y, Teruya K, Kikuchi Y, and Oka S. Successful absorption of antiretroviral drugs after gastrojejunal bypass surgery following failure of therapy through a jejunal tube. Intern Med. (Case Report) 48(12):1103-1104, 2009.
Davaalkham J, Unenchimeng P, Baigalmaa Ch, Oyunbileg B, Tsuchiya K, Hachiya A, Gatanaga H , Nyamkhuu D, and Oka S. High-risk status of HIV-1 infection in the very low epidemic country, Mongolia, 2007. Int J STD AIDS. 20(6):391-394, 2009.

Ishizaki A, Cuong NH, Thuc PV, Trung NV, Saijoh K, Kageyama S, Ishigaki K, Tanuma J, Oka S, and Ichimura H. Profile of HIV type 1 infection and genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV type 1-infected individuals in Hai Phong, Viet Nam. AIDS Res Hum Retroviruses. 25(2):175-182, 2009. 

Aoki M, Venzon DJ, Koh Y, Aoki-Ogata H, Miyakawa T, Yoshimura K, Maeda K, and Mitsuya H. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors. J Virol. 83(7):3059-3068, 2009.
  Koh Y, Das D, Leschenko S, Nakata H, Ogata-Aoki H, Amano M, Nakayama M, Ghosh AK, and Mitsuya H. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother. 53(3):997-1006, 2009.

Hachiya A, Shimane K, Sarafianos SG, Kodama EN, Sakagami Y, Negishi F, Koizumi H, Gatanaga H, Matsuoka M, Takiguchi M, and Oka S. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment- naïve patients. Antiviral Res. 82(3):115-121, 2009.

Motozono C, Yanaka S, Tsumoto K, Takiguchi M, and Ueno T. Impacts of intrinsic cooperative thermodynamics of peptide-MHC complexes on antiviral activity of HIV-specific CTL. J Immunol. 182(9):5528-5536, 2009.
Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, Gatanaga H, Fujiwara M, Hachiya A, Koizumi H, Kuse N, Oka S, Duda A, Prendergast A, Crawford H, Leslie A, Brumme Z, Brumme C, Allen T, Brander C, Kaslow R, Tang J, Hunter E, Allen S, Mulenga J, Branch S, Roach T, John M, Mallal S, Ogwu A, Shapiro R, Prado JG, Fidler S, Weber J, Pybus OG, Klenerman P, Ndung’u T, Phillips R, Heckerman D, Harrigan PR, Walker BD, Takiguchi M*, and Goulder P* (*equally contribution). Adaptation of HIV-1 to Human Leukocyte Antigen class I. Nature 458(7238): 641-645, 2009.
Murakoshi H, Kitano M, Akahoshi T, Kawashima Y, Dohki S, Oka S, and Takiguchi M.  Identification and characterization of 2 HIV-1 Gag immunodominant epitopes restricted by Asian HLA allele HLA-B*4801. Hum Immunol. 70(3):170-174, 2009.
Koizumi H, Iwatani T, Tanuma J, Fujiwara M, Izumi T, Oka S, and Takiguchi M.  Escape mutation selected by Gag28-36-specific cytotoxic T cells in HLA-A*2402-positive HIV-1-infected donors. Microbes Infect. 11(2):198-204, 2009.
Gatanaga H, and Oka S. Successful genotype-tailored treatment with small-dose efavirenz. AIDS. (correspondence) 23(3):433-434, 2009.

Gatanaga H, Tsukada K, Honda H, Tanuma J, Yazaki H, Watanabe T, Honda M, Teruya K, Kikuchi Y, and Oka S. Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor. Clin Infect Dis. (correspondence) 48(2):260-262, 2009.

Bi X, Suzuki Y, Gatanaga H, and Oka S. High frequency and proliferation of CD4+ FOXP3+ Treg in HIV-1-infected patients with low CD4 counts. Eur J Immunol. 39(1):301-309, 2009.




Previous Page Page top